ERK Inhibitor JSI-1187 in Advanced Solid Tumors
JSI-1187-101 phase 1 study
Solid Tumor|NSCLC|Melanoma
DRUG: JSI-1187
Adverse Event, An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment., through study completion, an average of 1 year|Serious Adverse Events, Any untoward medical occurrence that at any dose:results in death、is life-threatening、requires inpatient hospitalization or prolongation of existing hospitalization、results in persistent or significant disability/incapacity,or is a congenital anomaly/birth defect, through study completion, an average of 1 year
Objective Response Rate, The proportion of patients with complete and partial responses., through study completion, an average of 1 year
This study is a multicenter, open-label, dose-escalation and dose- expansion phase I clinical study. To investigate the safety, tolerability and PK characteristics of JSI-1187 capsule in Chinese patients with advanced solid tumors harboring MAPK signaling pathway mutations, and to evaluate the efficacy of JSI-1187 capsule in the treatment of advanced solid tumors harboring MAPK signaling pathway mutations.